Other Clinical Trial - This is an Open-label, Single Arm Study to Evaluate

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03140943` - Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma	Phase 2
Recruiting	`NCT05066022` - A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma	N/A
Recruiting	`NCT06182696` - OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM	Phase 1/Phase 2
Recruiting	`NCT03715478` - Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex	Phase 1/Phase 2
Completed	`NCT02917941` - A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma	Phase 2
Not yet recruiting	`NCT03903406` - Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study
Completed	`NCT03242460` - The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)	Phase 2
Terminated	`NCT03836053` - Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma	Phase 1
Recruiting	`NCT05719701` - Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma	Phase 1/Phase 2
Recruiting	`NCT05297240` - Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
Terminated	`NCT04272775` - A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)	Phase 1
Not yet recruiting	`NCT06351644` - ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma	Phase 1/Phase 2
Withdrawn	`NCT04392648` - A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Phase 1
Active, not recruiting	`NCT01632150` - Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma	Phase 2
Completed	`NCT02831686` - A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma	Phase 1
Recruiting	`NCT06153251` - A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma	Phase 1
Completed	`NCT00882063` - Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma	Phase 1/Phase 2
Terminated	`NCT04017130` - A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma	Phase 1
Completed	`NCT03416374` - A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy	Phase 4
Completed	`NCT03170882` - A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma	Phase 2

NCT number	NCT05486975
Study type	Interventional
Source	The First Affiliated Hospital of Soochow University
Contact	Chengcheng Fu
Phone	13962191404
Email	fuzhengzheng@suda.edu.cn
Status	Recruiting
Phase	Early Phase 1
Start date	August 10, 2022
Completion date	January 29, 2025

This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms